The Irish Cancer Society was the only Patient Advocacy Group from Ireland selected to present its innovative patient partnership model at ASCO 2026, the world's largest oncology conference.
Johnson & Johnson has partnered with Myeloma Ireland as lead sponsor of the gold medal-winning ‘Rooted in Resilience’ garden at Bloom 2026.
Johnson & Johnson has announced European approval for eligible multiple myeloma patients or caregivers to self-administer DARZALEX® from the fifth dose onwards.
Stakeholders at the AXIS Patient Access Conference in Dublin heard that Ireland must agree a clear operational roadmap to meet its 180-day reimbursement decision target.
Beacon Hospital has marked a major milestone with the first brick laid on its €100m eight-storey expansion, which will add 70 new beds and a new Emergency Department.
Beacon Hospital has treated the first patient in Ireland and the UK using RapidArc Dynamic radiotherapy technology. Delivered through the Varian TrueBeam system, the platform offers exceptional precision, faster planning and treatment times, and greater protection of healthy tissue in cancer care.
Gilead Sciences and Kite have confirmed that Tecartus (brexucabtagene autoleucel), the first CAR T therapy for relapsed or refractory adult B-cell precursor acute lymphoblastic leukaemia, is now reimbursed in Ireland, offering a personalised treatment option supported by pivotal ZUMA-3 trial data.
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis AUTHOR: E. J. Bass, A.…
Written by Ciarán D’Arcy, Communications Officer, Irish Cancer Society Cancer care was particularly challenging due to the dual threats of Covid and the HSE cyberattack. The Irish Cancer…
Written by Dr Iseult Browne, Oncology Specialist Registrar and Dr Mark Doherty, Consultant Medical Oncologist, St Vincent’s University Hospital Lung cancer is the fourth most common type in…
